SI
NBIX icon

Shaker Investments’s Neurocrine Biosciences NBIX Stock Holding History

Shaker Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,501
Closed -$211K – 98
2025
Q3 		$211K Sell
1,501
-354
-19% -$48K 0.08% 95
2025
Q2 		$233K Hold
1,855
– – 0.1% 93
2025
Q1 		$205K Buy
+1,855
New +$235K 0.1% 94

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Shaker Investments's NBIX Position: Q4 2025 in Review

Shaker Investments sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 1,501 shares — an estimated $211K sold.

Shaker Investments first reported a position in NBIX in Q1 2025 and held it in 3 quarters. The position peaked at $233K in Q2 2025. 733 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Shaker Investments reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Shaker Investments sold 1,501 Neurocrine Biosciences shares in Q4 2025, an estimated $211K.
  • Shaker Investments first reported a position in Neurocrine Biosciences in Q1 2025 and held it in 3 quarters.
  • Shaker Investments's Neurocrine Biosciences position peaked at $233K in Q2 2025.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Shaker Investments's 13F filing for Q4 2025, filed 30 Jan 2026.